TPMT

Across TCGA pan-cancer cohorts, TPMT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TPMT data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TPMT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TPMT expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where TPMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.929	0.615	<.001	46	view →
PDAC	DFS	Tertile	II,III,IV	0.406	0.194	.008	21	view →
HNSC	DFS	Median	II,III,IV	0.738	0.546	.019	8	view →
GBM	OS	Median	All	0.778	0.932	.015	7	view →
COAD	DFS	Median	III,IV	0.887	1.000	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TPMT–LSCC (DFS)

Open the LSCC breakdown →